Quarterly report pursuant to Section 13 or 15(d)

Note 3 - Business Combinations

Note 3 - Business Combinations
6 Months Ended
Jun. 30, 2021
Notes to Financial Statements  
Business Combination Disclosure [Text Block]


Business Combinations


Acquisitions Accounted for Using the Purchase Method


On January 31, 2021, the Company closed on the acquisition of substantially all of the assets of FilAMed, a privately-held biomedical services company based in Bakersfield, California. This acquisition will supplement the Company’s existing biomedical recertification, maintenance and repair services for acute care facilities and other alternate site settings including home care and home infusion providers, skilled nursing facilities, pain centers and others.


On April 18, 2021, the Company acquired the business and substantially all of the assets of OB Healthcare Corporation (“OB Healthcare”), a privately-held biomedical services company based in Austin, Texas. OB Healthcare specializes in on-site repair, preventative maintenance, and device physical inventory management to hospitals and healthcare systems nationwide. The acquisition further develops and expands InfuSystem’s Durable Medical Equipment Services (“DME Services”) segment and complements the Company’s purchase of FilAMed.


FilAMed and OB Healthcare’s results of operations are included in the Company’s consolidated statements of operations from the respective closing dates. Revenues and earnings from these acquisitions has not been significant through June 30, 2021.


Purchase Price Allocation


Pursuant to FASB Accounting Standards Codification (“ASC”) Topic 805,Business Combinations,” the purchase price for each of the acquisitions was allocated to the assets acquired and liabilities assumed based upon their estimated fair values as of the respective acquisition dates. The purchase price allocations were primarily based upon a valuation using management’s estimates and assumptions. The purchase price allocation was completed for FilAMed as of June 30, 2021. The purchase price allocation for OB Healthcare was based on a preliminary analysis and is subject to further adjustments related to the final working capital. Upon completion of the final purchase price allocation, the Company may need to adjust the accounts receivable. The following table summarizes the consideration paid and the allocation of the purchase price to the fair values of the assets acquired and liabilities assumed as of the respective acquisition dates for both FilAMed and OB Healthcare (in thousands):












  $ 1,400     $ 6,250     $ 7,650  

Working capital (a)

    -       328       328  

Contingent consideration

    -       750       750  

Total - consideration

  $ 1,400     $ 7,328     $ 8,728  









Acquisition Date

Fair Value


Accounts receivable (a)

  $ -     $ 727     $ 727  


    74       -       74  

Medical equipment held for sale or rental

    40       -       40  

Property and equipment

    102       59       161  

Intangible assets

    1,015       3,000       4,015  


    169       3,542       3,711  

Operating lease right of use assets

    281       7       288  

Operating lease liabilities

    (281 )     (7 )     (288 )

Total - purchase price (a)

  $ 1,400     $ 7,328     $ 8,728  


(a) Amount based on preliminary working capital


During the three months ended June 30, 2021, the Company completed the valuation of FilAMed with immaterial changes in medical equipment held for sale or rental and intangible assets as well as the recognition of operating lease right of use assets and operating lease liabilities with a corresponding increase to goodwill. This decreased amortization expense by an immaterial amount for the three months ended June 30, 2021. The amount of acquisition costs for both transactions was $0.1 million and is included in general and administrative expenses.


On the FilAMed acquisition date, the Company made an initial cash payment of $1.2 million with a remaining liability of $0.2 million, which was paid during the quarter ended June 30, 2021. On the OB Healthcare acquisition date, the Company made an initial cash payment of $6.1 million and had additional estimated amount due to the seller of $0.5 million, primarily related to a working capital adjustment, and contingent consideration of $0.8 million, both of which were recorded in the balance sheet under the heading for other current liabilities. The contingent consideration arrangement requires the Company to pay OB Healthcare $0.8 million if certain written contracts are executed by December 31, 2021. The Company expects OB Healthcare to satisfy this requirement. As of June 30, 2021, the Company had a $1.2 million remaining liability.


The following table shows the breakdown of the identified intangible assets acquired into major intangible asset classes for both acquisitions:



Acquisition Date

Fair Value




Amortization Period



Customer relationships

  $ 2,300       15  

Unpatented technology

    943       7  

Non-competition agreements

    472       5  

Internal-use software

    300       5  

Total intangible assets (a)

  $ 4,015       11.2  


(a) There was no residual value, renewal terms or extensions associated with any intangible assets acquired.


The goodwill acquired consists of expected synergies from combining operations of FilAMed and OB Healthcare with the DME Services segment as well as their respective assembled workforce who have specialized knowledge and experience. All of the goodwill is deductible for tax purposes.


Unaudited Pro Forma Financial Information


The unaudited pro forma financial information in the table below summarizes the combined results of operations of the Company, FilAMed and OB Healthcare as though the companies’ businesses had been combined as of the beginning of the three and six month periods ended June 30, 2020. The pro forma financial information for the three months and six months ended June 30, 2021 has been adjusted by $0.1 million for the tax effected amount of acquisition costs and non-recurring expenses directly attributable to the FilAMed and OB Healthcare acquisitions. The three months and six months ended June 30, 2020 also included these charges. The pro forma financial information is presented for informational purposes only and is not indicative of the results of operations that would have been achieved if the acquisitions had taken place at the beginning of each period presented nor is it indicative of future results. The following pro forma financial information presented also includes the pro forma depreciation and amortization charges from acquired tangible and intangible assets for the three and six months ended June 30, 2021 and 2020 (in thousands):



Three months ended

June 30,


Six months ended

June 30,











  $ 25,035     $ 26,835     $ 50,067     $ 49,538  

Net income

  $ 1,001     $ 3,743     $ 990     $ 3,489